Neuromuscular paralysis as a pharmacodynamic probe to assess organ function during liver transplantation.
Potential for assessing liver function during liver transplantation surgery by monitoring muscle paralysis from nondepolarizing neuromuscular blockers that are hepatically cleared is critically assessed. Rocuronium is strongly favored as a promising pharmacodynamic probe for predicting allograft liver function because it is predominantly eliminated via the liver and its putative metabolites are not active. Prolongation of recovery from rocuronium paralysis is closely correlated with allograft liver function postoperatively. Vecuronium, pancuronium, and perhaps pipecuronium may also prove to be useful probes, but the two former blockers have active metabolites. Further prospective studies are necessary with more precise measurement of neuromuscular function to confirm the predictive value of this method. Alterations in neuromuscular blocker plasma concentrations that are correlated with changes in liver function and either the dose required or the intensity or duration of paralysis needs to be demonstrated for this technique to be clinically useful.
Gao
L
L
Department of Anaesthesia and Faculty of Pharmacy, University of Sydney, Sydney, Australia.
Ramzan
I
I
Baker
B
B
D000732:Androstanols / Q000493:pharmacokinetics; D000818:Animals; D006801:Humans; D008099:Liver / Q000378:metabolism*; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000502:physiology*; D016343:Monitoring, Intraoperative; D019148:Neuromuscular Blockade; D003473:Neuromuscular Nondepolarizing Agents / Q000493:pharmacokinetics*; D011237:Predictive Value of Tests; D000077123:Rocuronium; D012680:Sensitivity and Specificity
D000732:Androstanols; D003473:Neuromuscular Nondepolarizing Agents; D000077123:Rocuronium